Witjes - Figure 36
Intravesical Chemotherapy in high risk patients
FIG. 36: A class of drugs that is being used systemically for invasive bladder cancer, taxanes, has also shown some promising results in small studies in NMI bladder cancer.[20-23] Combination chemotherapy with gemcitabine plus a taxane is used in invasive metastatic bladder cancer, and so it has also been tried in NMI bladder cancer.[22] This Figure describes a small series of patients given gemcitabine plus docetaxel intravesically that showed a 54% disease-free survival at 1 year.[23] This will be followed with a larger Phase 2/3 trial.
References
Lu Z, Yeh TK, Wang J, et al. Paclitaxel gelatin nanoparticles for intravesical bladder cancer therapy. J Urol. 2011;185:1478−83 http://dx.doi.org/10.1016/j.juro.2010.11.091
McKiernan JM, Barlow LJ, Laudano MA, et al. A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guérin refractory nonmuscle invasive bladder cancer. J Urol. 2011;186:448−51 http://dx.doi.org/10.1016/j.juro.2011.03.129
Barlow LJ, McKiernan JM, Benson MC, et al. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy. J Urol. 2013;189:834−9 http://dx.doi.org/10.1016/j.juro.2012.10.068
Steinberg RL, Thomas LJ, O’Donnell MA, Nepple KG. Sequential Intravesical gemcitabine and docetaxel for the salvage treatment of non-muscle invasive bladder cancer. Bladder Cancer. 2015;1:65–72 https://doi.org/10.3233/BLC-150008
